Athira Pharma, Inc. — Director's Dealing 2025

Dec 29, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2025-12-24

Reporting Person: Renninger Robert (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-24	Stock Option (Right to Buy)	$4.07	A	34358	Acquired	2035-09-23	Common Stock (34358)	Direct

Footnotes

F1: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.

F2: On September 24, 2025, the reporting person was granted an option to purchase 34,358 shares of common stock. The option was scheduled to vest only upon satisfaction of both a milestone requirement (the "Milestone Requirement") and a service-based requirement (the "Service-Based Requirement"). The Milestone Requirement was satisfied on December 23, 2025. The Service-Based Requirement will be satisfied as to 50% of the total number of shares granted under the option on December 23, 2026 and as to 1/36th of the remaining 50% on the 23rd day of each month thereafter, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2020 Equity Incentive Plan) through the applicable vesting dates.